393 hasil
Menampilkan 1–20 · 0,09 detik · RSS
Liver Cancer, Pp 1-19 (2026)
Scopus
ISSN 1664-5553 · Karger Publishers · 393 artikel di indeks
-
Artikel Jurnal
Dissecting the transcriptomic profile of CD163+ macrophages in HCC with VETC+ angiogenesis provides potential targets of treatment
HCC is characterized by a highly vascularized tumor microenvironment (TME), with VETC being a distinctive, frequent and prognostically unfavourable type of this vascular TME. VETC+ HCCs show lymphocyte deprivation and enrichment with large, foamy macrophages distributed close to endothelial cells…
-
Artikel Jurnal
Lenvatinib Added to Nivolumab and Ipilimumab Improves Tumor Control and Progression-Free Survival in Unresectable Hepatocellular Carcinoma
Background In CheckMate-9DW, the suboptimal early tumor control of nivolumab–ipilimumab resulted in higher early mortality compared with the sorafenib/lenvatinib arm during the first 12 months. We evaluated whether adding lenvatinib to nivolumab–ipilimumab (NIL) improves outcomes versus…
-
Artikel Jurnal
Definition of Conversion Therapy and Neoadjuvant Therapy for Hepatocellular Carcinoma: A Consensus Guideline from the Japan Liver Cancer Association
With the advent of novel systemic therapies that provide high response rates, such as lenvatinib, atezolizumab–bevacizumab, durvalumab–tremelimumab, and nivolumab–ipilimumab, treatment strategies for patients with advanced hepatocellular carcinoma (HCC) have markedly evolved, and discussions on…
-
Artikel Jurnal
Carvedilol versus Propranolol in Patients with Hepatocellular Carcinoma: A Nationwide Cohort Study
Introduction: Beta-blockers reduce portal hypertension, however, evidence comparing carvedilol and propranolol in patients with hepatocellular carcinoma (HCC) is lacking. We aimed to compare the clinical outcomes of carvedilol versus propranolol in patients with HCC. Methods: Using the Korean…
-
Artikel Jurnal
THE REGENERATION PARADOX IN LIVER CANCER: HOW CHRONIC INJURY TRANSFORMS HEALING INTO CARCINOGENESIS
Background: The liver presents a fundamental paradox: it possesses unparalleled regenerative capacity yet demonstrates exquisite cancer susceptibility under chronic injury, with 85-90% of hepatocellular carcinoma (HCC) arising from chronic liver disease. Despite decades of research, the field lacks…
-
Artikel Jurnal
Lenvatinib Versus Sorafenib in First-Line Treatment of Older Patients With Unresectable Hepatocellular Carcinoma: A Subgroup Analysis of the REFLECT Trial
Background: In the open-label, phase 3 REFLECT trial, lenvatinib had noninferior overall survival (OS) to sorafenib, as well as improved progression-free survival (PFS) and objective response rate (ORR) in patients with unresectable hepatocellular carcinoma (uHCC). We report post hoc safety and…
-
Artikel Jurnal
Alcohol plays a detrimental role in the prognosis of hepatocellular carcinoma related to steatotic liver disease
Introduction: The recently adopted nomenclature of steatotic liver disease (SLD) introduces new diagnostic categories, including metabolic dysfunction-associated steatotic liver disease (MASLD), the intermediate metabolic dysfunction and alcohol-related liver disease (MetALD), and…
-
Artikel Jurnal
An updated systematic review and meta-analysis of modern radiotherapy techniques for hepatocellular carcinoma
Introduction: The practice of radiotherapy (RT) is worldwide transitioning from 3-dimensional conformal RT to modern RT techniques for hepatocellular carcinoma (HCC); however, evidence remains insufficient to determine whether these advanced RT techniques improve treatment outcomes. Therefore, we…
-
Artikel Jurnal
Comparison of Annual Dynamic Abbreviated MRI and Biannual Ultrasound for HCC Surveillance in a High-Risk Group: Two-Center Cohort Study
Introduction: Biannual ultrasound (US) is recommended for HCC surveillance, although its sensitivity for early-stage HCC is low. This study aims to compare the performance of annual dynamic abbreviated MRI (D-AMRI) and biannual US for HCC detection. Methods: This prospective, two-center cohort…
-
Artikel Jurnal
Comparative Study of Laparoscopic Hepatectomy, Open Hepatectomy, and Percutaneous Radiofrequency Ablation for Small Hepatocellular Carcinoma: An Ancillary Study of the SURF Trial
Background: Laparoscopic hepatectomy (LH) for hepatocellular carcinoma (HCC) is increasing. To evaluate the efficacy of LH for small HCC (≤3 tumors within ≤3 cm), we compared short- and long-term outcomes between LH, open hepatectomy (OH), and radiofrequency ablation (RFA) as an ancillary study of…
-
Artikel Jurnal
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study
Introduction: The potential for curative conversion with immunotherapy-based systemic treatment used with noncurative intent in patients with hepatocellular carcinoma (HCC) remains debated. This study aimed to provide a reliable epidemiological snapshot of response patterns to atezolizumab plus…
-
Artikel Jurnal
Real-World Treatment Patterns and Clinical Outcomes in Patients with Unresectable Hepatocellular Carcinoma: Results from the OREIOS Study
Background: OREIOS (NCT05239507) study determined the clinical characteristics, management patterns, and survival outcomes in patients with unresectable HCC (uHCC) from 12 countries across Asia, Latin America, and Middle East and Africa. Methods: This non-interventional, retrospective study…
-
Artikel Jurnal
Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup Analysis
Introduction: In the preplanned interim analysis of the phase 3 CheckMate 9DW trial, first-line nivolumab plus ipilimumab demonstrated significant overall survival (OS) benefit versus lenvatinib or sorafenib (hazard ratio [HR] = 0.79; 95% confidence interval [CI]: 0.65–0.96; p = 0.018) in patients…
-
Artikel Jurnal
Vessels That Encapsulate Tumor Cluster+ Unresectable Hepatocellular Carcinomas Benefit of Antiangiogenic Therapy
Introduction: Two distinct molecular groups of HCC have been recently associated with a better response to atezolizumab-bevacizumab. One of these, “angiogenesis-driven,” is related to HCC vascularization. Vessels that encapsulate tumor clusters (VETCs) is a morphological form of angiogenesis…
-
Artikel Jurnal
Disease Complexity and Nodule-Specific Responses to Atezolizumab plus Bevacizumab in Advanced Hepatocellular Carcinoma
Background: Advanced hepatocellular carcinoma (HCC) presents a range of presentations and responses to immunotherapy. We sought to determine the effects of Atez/Bev in patients with advanced HCC and various prognostic factors. Methods: We analyzed 183 patients with advanced HCC who received…
-
Artikel Jurnal
Surrogate Endpoints for Overall Survival in Advanced Hepatocelluar Carcinoma in the Era of Immunotherapy: A Trial Level Meta-Analysis
Background: Systemic therapy containing immune checkpoint inhibitors (ICIs) has become the standard of care for patients with advanced hepatocellular carcinoma (HCC). A prior analysis from the pre-ICI era demonstrated a moderate correlation between progression-free survival (PFS) and overall…
-
Artikel Jurnal
Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis
Background: Immune checkpoint inhibitors (ICI) are a keystone in advanced hepatocellular carcinoma (aHCC) therapy. However, preclinical evidence suggests that mice with pure metabolic dysfunction-associated steatohepatitis (MASH)-related HCCs may not benefit from ICIs. This has tremendous…
-
Artikel Jurnal
Adverse Event Monitoring with Imaging: Prognostic Significance in Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma
Introduction: Immune checkpoint inhibitors (ICIs) have emerged as the first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). Emerging evidence suggests that immune-related adverse events (irAEs) may be associated with improved ICI efficacy. This study evaluated the impact of…
-
Artikel Jurnal
Proton Beam Therapy for Untreated Hepatocellular Carcinoma Unsuitable for Transcatheter Arterial Chemoembolization
Introduction: Intermediate-stage hepatocellular carcinoma (HCC) derives limited benefit from transarterial chemoembolization (TACE), which has led to introduction of the concept of “TACE-unsuitable HCC.” Drug therapy may be more beneficial, but intrahepatic lesion control tends to be a problem…